Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Journal:
Drug Delivery Letters
Volume:
6
Page:
46-56
Author(s):
Kaitlin L. Nufer, Miko Yamada and Tarl W. Prow
Recent Trends on the Use of Nanoparticles for Nitric Oxide Delivery in Antimicrobial Applications
Journal:
Drug Delivery Letters
Volume:
6
Page:
3-10
Author(s):
Sayeed Hasan, Nicky Thomas, Benjamin Thierry, Sarah Vreugde, Peter-John Wormald and Clive A. Prestidge
Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy
Journal:
Current Drug Delivery
Volume:
13
Page:
1176-1182
Author(s):
Mohammad Yahya Hanafi-Bojd, Mahmoud Reza Jaafari, Navid Ramezanian, Khalil Abnous and Bizhan Malaekeh-Nikouei
Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior
Journal:
Current Drug Delivery
Volume:
13
Page:
1065-1070
Author(s):
Zahra Ali Mohammadi, Seyed Foad Aghamiri, Ali Zarrabi and Mohammad Reza Talaie
A Nanostructured Silica-Lipid Hybrid to Facilitate Oral SN-38-based Chemotherapy
Journal:
Drug Delivery Letters
Volume:
6
Page:
11-17
Author(s):
Thilagavathi Yuvaraj, Shasha Rao, Tri-Hung Nguyen, Ben J. Boyd and Clive A. Prestidge
miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF
Journal:
Current Cancer Drug Targets
Volume:
16
Page:
807-817
Author(s):
Benping Zhang, Ling Ma, Jia Wei, Jingyu Hu, Zichu Zhao, Youping Wang, Yan Chen and Fei Zhao
Meet Our Editorial Board Member
Journal:
Current Cancer Drug Targets
Volume:
16
Page:
737-737
Author(s):
Ingunn Holen
Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Journal:
Current Cancer Drug Targets
Volume:
16
Page:
773-788
Author(s):
Reza Salarinia, Amirhossein Sahebkar, Mostafa Peyvandi, Hamid Reza Mirzaei, Mahmoud Reza Jaafari, Maryam Matbou Riahi, Hamed Ebrahimnejad, Javid Sadri Nahand, Jamshid Hadjati, Mobina Ostadi Asrami, Sara Fadaei, Rasoul Salehi and Hamed Mirzaei
Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Journal:
Current Cancer Drug Targets
Volume:
16
Page:
755-764
Author(s):
Senthamil R. Selvan, John P. Dowling, William K. Kelly and Jianqing Lin
E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Journal:
Current Cancer Drug Targets
Volume:
16
Page:
765-772
Author(s):
Yulin Huang, Rui Chen and Jianwei Zhou